2005 주식 개요 투자 지주 회사인 SSY 그룹은 중화인민공화국 및 전 세계의 병원과 유통업체에 다양한 의약품을 연구, 개발, 제조, 거래 및 판매하는 회사입니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 SSY Group 과거 주가 현재 주가 HK$3.37 52주 최고치 HK$5.20 52주 최저치 HK$3.26 베타 0.62 1개월 변경 -11.55% 3개월 변경 사항 -11.55% 1년 변경 사항 -28.30% 3년 변화 -12.92% 5년 변화 -47.34% IPO 이후 변화 -51.16%
최근 뉴스 및 업데이트
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) Nov 05
SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China Oct 21
SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China Oct 14 더 많은 업데이트 보기
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) Nov 05
SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China Oct 21
SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China Oct 14
Investor sentiment improves as stock rises 18% Oct 02
Chairman & CEO recently bought HK$4.8m worth of stock Sep 25
SSY Group Limited Announces Update on Product Development Sep 09
Chairman & CEO recently bought HK$1.5m worth of stock Sep 04
SSY Group Limited Announces Update on Product Development Sep 02
First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023) Aug 31
First half dividend increased to HK$0.08 Aug 30 SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024
SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
SSY Group Limited Announces Update on Product Development Aug 07
Investor sentiment deteriorates as stock falls 16% Jul 29
SSY Group Limited Announces Update on Product Development Jul 23
SSY Group Limited Announces Update on Product Development Jul 16
SSY Group Limited Announces Update on Product Development Jun 29
SSY Group Limited Announces Update on Product Development Jun 24
SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jun 18
SSY Group Limited Announces Update on Product Development Jun 08 SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China
SSY Group Limited Announces Update on Product Development May 29
Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China May 28
Upcoming dividend of HK$0.10 per share May 14
SSY Group Limited Provides Update on Product Development Apr 03
Chairman & CEO recently bought HK$2.5m worth of stock Mar 29
SSY Group Limited, Annual General Meeting, May 17, 2024 Mar 28
Full year 2023 earnings released: EPS: HK$0.44 (vs HK$0.38 in FY 2022) Mar 28
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024 Mar 27
SSY Group Limited Announces Update on Product Development Mar 21
SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China Mar 02
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market Mar 01
SSY Group Limited Receives Approval for Gliclazide Tablet Feb 28
SSY Group Limited Provides Update on Product Development Feb 24
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China Feb 19
SSY Group Limited Announces Update on Product Development Jan 31
SSY Group Limited Provides Update on Product Development Jan 24 SSY Group Limited Appoints Liu Wenjun as Non-Executive Director
Ssy Group Limited Provides Update on Product Development Jan 17
SSY Group Limited Announces Update on Product Development Jan 10
SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jan 05
SSY Group Limited Provides Update on Product Development Dec 27
Chairman & CEO recently bought HK$4.7m worth of stock Dec 06
SSY Group Limited Announces Update on Product Development Dec 01
SSY Group Limited Announces Update on Product Development Nov 23
SSY Group Limited Announces Update on Product Development Nov 10
National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045 Nov 09
SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023 Nov 02
SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection Nov 01
SSY Group Limited Announces Update on Product Development Oct 31
SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China Oct 27
SSY Group Limited Provides Update on Product Development Oct 26
SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection Oct 21
SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China Oct 18
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China Oct 12
SSY Group Limited Announces Update on Product Development Oct 10
SSY Group Limited Announces Update on Product Development Sep 16
Upcoming dividend of HK$0.07 per share at 3.5% yield Sep 07
SSY Group Limited Announces Update on Product Development Sep 05
SSY Group Limited Provides Update on Product Development Sep 02
First half 2023 earnings released: EPS: HK$0.21 (vs HK$0.19 in 1H 2022) Aug 30
Ssy Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 27 September 2023 Aug 30
SSY Group Limited Announces Update on Product Development Aug 24
SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023 Aug 18
SSY Group Limited Obtains Approval for Drug Production and Registration for Stiripentol for Suspension (500Mg and 250Mg) from the National Medical Products Administration of China Jul 28
SSY Group Limited Obtains Approval for Drug Production and Registration for Oseltamivir Phosphate for Suspension Jul 14
Chairman & CEO recently bought HK$8.3m worth of stock Jul 08
SSY Group Limited Provides Update on Product Development Jul 07
SSY Group Limited Announces Update on Product Development Jun 30
SSY Group Limited Obtains Approval for Drug Production and Registration for Citicoline Sodium Injection from the National Medical Products Administration of China Jun 14
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Urapidil Hydrochloride Injection Jun 03
SSY Group Limited Announces Update on Product Development May 31
SSY Group Limited Announces the Retirement of Mr. Leung Chong Shun as Independent Non-Executive Director, Chairman of the Remuneration Committee of the Company, A Member F the Audit Committee of the Company and A Member of the Nomination Committee May 20
Upcoming dividend of HK$0.08 per share at 2.8% yield May 16
SSY Group Limited Announces Update on Product Development May 13
SSY Group Limited Announces Update on Product Development May 12
Chairman & CEO recently bought HK$4.9m worth of stock May 10
SSY Group Limited Announces Update on Product Development May 09
Chairman & CEO recently bought HK$2.1m worth of stock Mar 30
Full year 2022 earnings released: EPS: HK$0.38 (vs HK$0.26 in FY 2021) Mar 29
Now 21% undervalued Mar 14
SSY Group Limited Announces the Group's Tinidazole Obtains the Approval for Registration from the National Medical Products Administration of China Feb 07
SSY Group Limited Updates on Product Development Jan 31
SSY Group Limited Obtains the Approval for Registration from the National Medical Products Administration of China to Become A Bulk Drug for the Preparations on the Market Jan 20
SSY Group Limited Obtains Approvals for Drug Production and Registration for Felodipine Sustained-Release Tablets (5mg) and Lacosamide Injection (20ml:0.2g) from the National Medical Products Administration of China Jan 06
Investor sentiment improved over the past week Jan 04
SSY Group Limited Announces Appointment of Jiang Guangce as an Independent Non-Executive Director and Member of Audit Committee, Nomination Committee and Remuneration Committee, with Effect from 1 January 2023 Dec 29
Less than half of directors are independent Nov 16
SSY Group Limited Obtains the Approval for Drug Production and Registration for Azithromycin Tablets (0.25G) from the National Medical Products Administration of China, Being Under Type 4 Chemical Drug and Regarded as Passing the Consistency Evaluation Nov 15
SSY Group Limited Obtains the Approval for Drug Productions from the National Medical Products Administration of China Oct 11
SSY Group Limited Announces Update on Product Development Sep 27
SSY Group Limited Announces Approval of Mecobalamin Injection by National Medical Products Administration of China Sep 14
Upcoming dividend of HK$0.06 per share Sep 09 주주 수익률 2005 HK Pharmaceuticals HK 마켓 7D -4.3% -1.9% -0.5% 1Y -28.3% -3.9% 19.9%
전체 주주 수익률 보기
수익률 대 산업: 2005 지난 1년 동안 -3.9 %를 반환한 Hong Kong Pharmaceuticals 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 2005 지난 1년 동안 19.9 %를 반환한 Hong Kong 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 2005's price volatile compared to industry and market? 2005 volatility 2005 Average Weekly Movement 5.3% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
안정적인 주가: 2005 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: 2005 의 주간 변동성 ( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 투자 지주회사인 SSY Group Limited는 중화인민공화국 및 전 세계의 병원과 유통업체에 다양한 의약품을 연구, 개발, 제조, 거래 및 판매하는 회사입니다. 이 회사는 비PVC 소프트 백, 업라이트 소프트 백, PP 플라스틱 병, 유리병 주입 솔루션, 앰플 주사제 등 정맥 주입 솔루션을 제공합니다. 또한 소량 주사제, 경구용 제제, 한약 제제, 생물학적 제제는 물론 벌크 의약품과 의료 재료도 제공합니다.
자세히 보기 SSY Group Limited 기본 사항 요약 SSY Group 의 수익과 매출은 시가총액과 어떻게 비교하나요? 2005 기본 통계 시가총액 HK$9.97b 수익(TTM ) HK$1.37b 수익(TTM ) HK$6.47b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 2005 손익 계산서(TTM ) 수익 HK$6.47b 수익 비용 HK$2.95b 총 이익 HK$3.52b 기타 비용 HK$2.15b 수익 HK$1.37b
주당 순이익(EPS) 0.46 총 마진 54.39% 순이익 마진 21.11% 부채/자본 비율 47.7%
2005 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기 기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/21 11:27 장 마감 주가 2024/12/20 00:00 수익 2024/06/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 SSY Group Limited 24 애널리스트 중 6 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Derrick Sun BNP Paribas Securities (Asia) Milo Liu BOCOM International Securities Limited Ying Shao BofA Global Research
21 더 많은 분석가 보기 
